Aldosterone and progression of kidney disease.

Monica Cortinovis, Norberto Perico, Dario Cattaneo, Giuseppe Remuzzi

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Experimental evidence indicates that aldosterone, besides its mineralcorticoid properties, directly contributes to accelerate renal damage through promotion of cell growth, fibrosis and inflammation. As a consequence, attenuation of growth-promoting and fibroproliferative effects of aldosterone might contribute to slow progression of chronic renal injury. Preliminary clinical observations have documented that aldosterone blockers added to angiotensin-converting enzyme inhibitor- and/or angiotensin receptor blocker-based regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies. Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases.

Original languageEnglish
Pages (from-to)133-143
Number of pages11
JournalTherapeutic Advances in Cardiovascular Disease
Volume3
Issue number2
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Kidney Diseases
Aldosterone
Kidney
Angiotensin Receptor Antagonists
Diabetic Nephropathies
Growth
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Fibrosis
Inflammation
Safety
Wounds and Injuries

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Aldosterone and progression of kidney disease. / Cortinovis, Monica; Perico, Norberto; Cattaneo, Dario; Remuzzi, Giuseppe.

In: Therapeutic Advances in Cardiovascular Disease, Vol. 3, No. 2, 04.2009, p. 133-143.

Research output: Contribution to journalArticle

@article{feeeb7cd671b41ceb3383fb9fc054c60,
title = "Aldosterone and progression of kidney disease.",
abstract = "Experimental evidence indicates that aldosterone, besides its mineralcorticoid properties, directly contributes to accelerate renal damage through promotion of cell growth, fibrosis and inflammation. As a consequence, attenuation of growth-promoting and fibroproliferative effects of aldosterone might contribute to slow progression of chronic renal injury. Preliminary clinical observations have documented that aldosterone blockers added to angiotensin-converting enzyme inhibitor- and/or angiotensin receptor blocker-based regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies. Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases.",
author = "Monica Cortinovis and Norberto Perico and Dario Cattaneo and Giuseppe Remuzzi",
year = "2009",
month = "4",
doi = "10.1177/1753944708100409",
language = "English",
volume = "3",
pages = "133--143",
journal = "Therapeutic Advances in Cardiovascular Disease",
issn = "1753-9447",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Aldosterone and progression of kidney disease.

AU - Cortinovis, Monica

AU - Perico, Norberto

AU - Cattaneo, Dario

AU - Remuzzi, Giuseppe

PY - 2009/4

Y1 - 2009/4

N2 - Experimental evidence indicates that aldosterone, besides its mineralcorticoid properties, directly contributes to accelerate renal damage through promotion of cell growth, fibrosis and inflammation. As a consequence, attenuation of growth-promoting and fibroproliferative effects of aldosterone might contribute to slow progression of chronic renal injury. Preliminary clinical observations have documented that aldosterone blockers added to angiotensin-converting enzyme inhibitor- and/or angiotensin receptor blocker-based regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies. Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases.

AB - Experimental evidence indicates that aldosterone, besides its mineralcorticoid properties, directly contributes to accelerate renal damage through promotion of cell growth, fibrosis and inflammation. As a consequence, attenuation of growth-promoting and fibroproliferative effects of aldosterone might contribute to slow progression of chronic renal injury. Preliminary clinical observations have documented that aldosterone blockers added to angiotensin-converting enzyme inhibitor- and/or angiotensin receptor blocker-based regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies. Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases.

UR - http://www.scopus.com/inward/record.url?scp=66149121107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66149121107&partnerID=8YFLogxK

U2 - 10.1177/1753944708100409

DO - 10.1177/1753944708100409

M3 - Article

C2 - 19171691

AN - SCOPUS:66149121107

VL - 3

SP - 133

EP - 143

JO - Therapeutic Advances in Cardiovascular Disease

JF - Therapeutic Advances in Cardiovascular Disease

SN - 1753-9447

IS - 2

ER -